Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (ATM and/or TP53, HR-FISH)...

Descripción completa

Detalles Bibliográficos
Autores: Puiggros Metje, Anna Maria, Salido Galeote, Marta, Ferrer Del Alamo, Ana, Gimeno Vázquez, Eva, Abella Monreal, Eugenia, Espinet Solà, Blanca
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/35116
Acceso en línea:http://hdl.handle.net/10230/35116
http://dx.doi.org/10.18632/oncotarget.17350
Access Level:acceso abierto
Palabra clave:Cariotips
Leucèmia limfoblàstica -- Aspectes genètics
ATM deletion
CLL
TP53 deletion
Complex karyotype
id ES_73600e2b4fa2b56dad9dc81898e730a0
oai_identifier_str oai:recercat.cat:10230/35116
network_acronym_str ES
network_name_str España
repository_id_str
spelling Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletionsPuiggros Metje, Anna MariaSalido Galeote, MartaFerrer Del Alamo, AnaGimeno Vázquez, EvaAbella Monreal, EugeniaEspinet Solà, BlancaCariotipsLeucèmia limfoblàstica -- Aspectes genèticsATM deletionCLLTP53 deletionComplex karyotypeGenomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (ATM and/or TP53, HR-FISH) in a cohort of 1045 untreated MBL/CLL patients. In all, 99/1045 (9.5%) patients displayed a CK. Despite ATM and TP53 deletions were more common in CK (25% vs 7%; P < 0.001; 40% vs 5%; P < 0.001, respectively), only 44% (40/90) patients with TP53 deletions showed a CK. CK group showed a significant higher two-year cumulative incidence of treatment (48% vs 20%; P < 0.001), as well as a shorter overall survival (OS) (79 mo vs not reached; P < 0.001). When patients were categorized regarding CK and HR-FISH, those with both characteristics showed the worst median OS (52 mo) being clearly distinct from those non-CK and non-HR-FISH (median not reached), but no significant differences were detected between cases with only CK or HR-FISH. Both CK and TP53 deletion remained statistically significant in the multivariate analysis for OS. In conclusion, CK group is globally associated with advanced disease and poor prognostic markers. Further investigation in larger cohorts with CK lacking HR-FISH is needed to elucidate which mechanisms underlie the poor outcome of this subgroupImpact Journals201820182017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/35116http://dx.doi.org/10.18632/oncotarget.17350reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésOncotarget. 2017 Apr 21;8(33):54297-303Copyright : © 2017 Puiggros et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.https://creativecommons.org/licenses/by/3.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/351162026-05-29T05:05:01Z
dc.title.none.fl_str_mv Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
title Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
spellingShingle Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
Puiggros Metje, Anna Maria
Cariotips
Leucèmia limfoblàstica -- Aspectes genètics
ATM deletion
CLL
TP53 deletion
Complex karyotype
title_short Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
title_full Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
title_fullStr Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
title_full_unstemmed Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
title_sort Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
dc.creator.none.fl_str_mv Puiggros Metje, Anna Maria
Salido Galeote, Marta
Ferrer Del Alamo, Ana
Gimeno Vázquez, Eva
Abella Monreal, Eugenia
Espinet Solà, Blanca
author Puiggros Metje, Anna Maria
author_facet Puiggros Metje, Anna Maria
Salido Galeote, Marta
Ferrer Del Alamo, Ana
Gimeno Vázquez, Eva
Abella Monreal, Eugenia
Espinet Solà, Blanca
author_role author
author2 Salido Galeote, Marta
Ferrer Del Alamo, Ana
Gimeno Vázquez, Eva
Abella Monreal, Eugenia
Espinet Solà, Blanca
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Cariotips
Leucèmia limfoblàstica -- Aspectes genètics
ATM deletion
CLL
TP53 deletion
Complex karyotype
topic Cariotips
Leucèmia limfoblàstica -- Aspectes genètics
ATM deletion
CLL
TP53 deletion
Complex karyotype
description Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (ATM and/or TP53, HR-FISH) in a cohort of 1045 untreated MBL/CLL patients. In all, 99/1045 (9.5%) patients displayed a CK. Despite ATM and TP53 deletions were more common in CK (25% vs 7%; P < 0.001; 40% vs 5%; P < 0.001, respectively), only 44% (40/90) patients with TP53 deletions showed a CK. CK group showed a significant higher two-year cumulative incidence of treatment (48% vs 20%; P < 0.001), as well as a shorter overall survival (OS) (79 mo vs not reached; P < 0.001). When patients were categorized regarding CK and HR-FISH, those with both characteristics showed the worst median OS (52 mo) being clearly distinct from those non-CK and non-HR-FISH (median not reached), but no significant differences were detected between cases with only CK or HR-FISH. Both CK and TP53 deletion remained statistically significant in the multivariate analysis for OS. In conclusion, CK group is globally associated with advanced disease and poor prognostic markers. Further investigation in larger cohorts with CK lacking HR-FISH is needed to elucidate which mechanisms underlie the poor outcome of this subgroup
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/35116
http://dx.doi.org/10.18632/oncotarget.17350
url http://hdl.handle.net/10230/35116
http://dx.doi.org/10.18632/oncotarget.17350
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Oncotarget. 2017 Apr 21;8(33):54297-303
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/3.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/3.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Impact Journals
publisher.none.fl_str_mv Impact Journals
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410805371371520
score 15.812429

Similares en LA Referencia